Miriam S Bettencourt1. 1. Advanced Dermatology and Cosmetic Surgery, Henderson, Nevada; Assistant Clinical Professor of Dermatology, University of Nevada, Las Vegas, Nevada.
Abstract
OBJECTIVE: To describe the safety, tolerability, and efficacy of treatment of actinic keratosis on the scalp with two consecutive, once-daily applications of ingenol mebutate gel, 0.05%. DESIGN: Retrospective chart review. SETTING: Community dermatology practice. PARTICIPANTS: Male patients (N=78) with a long history of recurrent and relapsed scalp actinic keratosis. MEASUREMENTS: This chart review extracted non-identifying information on patients' medical history, pertinent history of actinic keratosis and skin cancer, and prior actinic keratosis treatments. Also collected was information on patients' treatment of scalp actinic keratosis with ingenol mebutate gel, 0.05%, including the occurrence of local skin reactions and their treatment, adverse events, and efficacy results at short-term and additional follow-up. RESULTS: In these patients, a significant proportion of the scalp had numerous actinic keratoses that were often recurrent and/or hyperkeratotic. Most patients (83%) received cryosurgery to visible scalp actinic keratoses two weeks before ingenol mebutate treatment. Local skin reactions developed on the first day of topical treatment, were predominantly mild or moderate in intensity, and generally were resolved by 10 to 14 days. Local skin reactions were treated with a topical moisturizing product in 44 percent of the patients. Nearly half (45%) of the patients experienced application-site reactions, described as a combination of burning, itching, pain, and/or tenderness; the reactions were mild or moderate in intensity and lasted only a few days. CONCLUSIONS: Ingenol mebutate gel, 0.05%, had a good safety and tolerability profile when used to treat scalp actinic keratosis in patients who had a prolonged history of actinic keratosis.
OBJECTIVE: To describe the safety, tolerability, and efficacy of treatment of actinic keratosis on the scalp with two consecutive, once-daily applications of ingenol mebutate gel, 0.05%. DESIGN: Retrospective chart review. SETTING: Community dermatology practice. PARTICIPANTS: Male patients (N=78) with a long history of recurrent and relapsed scalp actinic keratosis. MEASUREMENTS: This chart review extracted non-identifying information on patients' medical history, pertinent history of actinic keratosis and skin cancer, and prior actinic keratosis treatments. Also collected was information on patients' treatment of scalp actinic keratosis with ingenol mebutate gel, 0.05%, including the occurrence of local skin reactions and their treatment, adverse events, and efficacy results at short-term and additional follow-up. RESULTS: In these patients, a significant proportion of the scalp had numerous actinic keratoses that were often recurrent and/or hyperkeratotic. Most patients (83%) received cryosurgery to visible scalp actinic keratoses two weeks before ingenol mebutate treatment. Local skin reactions developed on the first day of topical treatment, were predominantly mild or moderate in intensity, and generally were resolved by 10 to 14 days. Local skin reactions were treated with a topical moisturizing product in 44 percent of the patients. Nearly half (45%) of the patients experienced application-site reactions, described as a combination of burning, itching, pain, and/or tenderness; the reactions were mild or moderate in intensity and lasted only a few days. CONCLUSIONS:Ingenol mebutate gel, 0.05%, had a good safety and tolerability profile when used to treat scalp actinic keratosis in patients who had a prolonged history of actinic keratosis.
Authors: Rajesh Balkrishnan; Kimberly A Cayce; Amit S Kulkarni; Thomas Orsagh; Jack R Gallagher; David Richmond; Steven R Feldman Journal: J Dermatolog Treat Date: 2006 Impact factor: 3.359
Authors: Mark Lebwohl; Neil Swanson; Lawrence L Anderson; Anita Melgaard; Zhenyi Xu; Brian Berman Journal: N Engl J Med Date: 2012-03-15 Impact factor: 91.245